Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Patients with pretreated estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis. Elacestrant is a novel, oral selective ER degrader that demonstrated activity in early studies. METHODS: This randomized, open-label, phase II...

Descripción completa

Detalles Bibliográficos
Autores principales: Bidard, Francois-Clement, Kaklamani, Virginia G., Neven, Patrick, Streich, Guillermo, Montero, Alberto J., Forget, Frédéric, Mouret-Reynier, Marie-Ange, Sohn, Joo Hyuk, Taylor, Donatienne, Harnden, Kathleen K., Khong, Hung, Kocsis, Judit, Dalenc, Florence, Dillon, Patrick M., Babu, Sunil, Waters, Simon, Deleu, Ines, García Sáenz, José A., Bria, Emilio, Cazzaniga, Marina, Lu, Janice, Aftimos, Philippe, Cortés, Javier, Liu, Shubin, Tonini, Giulia, Laurent, Dirk, Habboubi, Nassir, Conlan, Maureen G., Bardia, Aditya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553388/
https://www.ncbi.nlm.nih.gov/pubmed/35584336
http://dx.doi.org/10.1200/JCO.22.00338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553388/
https://www.ncbi.nlm.nih.gov/pubmed/35584336
http://dx.doi.org/10.1200/JCO.22.00338

Ejemplares similares